{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:32:23Z","timestamp":1791923543863,"version":"4.3.4"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,5,24]],"date-time":"2013-05-24T00:00:00Z","timestamp":1369353600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1007\/s12185-013-1370-4","type":"journal-article","created":{"date-parts":[[2013,5,23]],"date-time":"2013-05-23T13:14:58Z","timestamp":1369314898000},"page":"24-33","source":"Crossref","is-referenced-by-count":71,"title":["Pathophysiology and management of primary immune thrombocytopenia"],"prefix":"10.1007","volume":"98","author":[{"given":"Hirokazu","family":"Kashiwagi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Tomiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,5,24]]},"reference":[{"key":"1370_CR1","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1056\/NEJMra010501","volume":"346","author":"DB Cines","year":"2002","unstructured":"Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002;346:995\u20131008.","journal-title":"N Engl J Med"},{"issue":"Suppl 5","key":"1370_CR2","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.seminhematol.2007.11.002","volume":"44","author":"R McMillan","year":"2007","unstructured":"McMillan R. The pathogenesis of chronic immune thrombocytopenic purpura. Semin Hematol. 2007;44(Suppl 5):S3\u201311.","journal-title":"Semin Hematol"},{"key":"1370_CR3","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood-2009-06-225565","volume":"115","author":"D Provan","year":"2010","unstructured":"Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115:168\u201386.","journal-title":"Blood"},{"key":"1370_CR4","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1182\/blood.V94.3.909.415k02_909_913","volume":"94","author":"H Frederiksen","year":"1999","unstructured":"Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood. 1999;94:909\u201313.","journal-title":"Blood"},{"key":"1370_CR5","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1046\/j.1365-2141.2003.04547.x","volume":"122","author":"AJ Neylon","year":"2003","unstructured":"Neylon AJ, Saunders PWG, Howard MR, Proctor SJ, Taylor PRA. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol. 2003;122:966\u201374.","journal-title":"Br J Haematol"},{"key":"1370_CR6","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2141.2009.07615.x","volume":"145","author":"WM Schoonen","year":"2009","unstructured":"Schoonen WM, Kucera G, Coalson J, Li L, Rutstein M, Mowat F, et al. Epidemiology of immune thrombocytopenic purpura in the general practice research database. Br J Haematol. 2009;145:235\u201344.","journal-title":"Br J Haematol"},{"key":"1370_CR7","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s12185-011-0791-1","volume":"93","author":"Y Kurata","year":"2011","unstructured":"Kurata Y, Fujimura K, Kuwana M, Tomiyama Y, Murata M. Epidemiology of primary immune thrombocytopenia in children and adults in Japan: a population-based study and literature review. Int J Hematol. 2011;93:329\u201335.","journal-title":"Int J Hematol"},{"key":"1370_CR8","first-page":"1","volume":"38","author":"WJ Harrington","year":"1951","unstructured":"Harrington WJ, Minnich V, Hollingsworth JW, Moore CV. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med. 1951;38:1\u201310.","journal-title":"J Lab Clin Med"},{"key":"1370_CR9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1172\/JCI113060","volume":"80","author":"PJ Ballem","year":"1987","unstructured":"Ballem PJ, Segal GM, Stratton JR, Gernsheimer T, Adamson JW, Slichter SJ. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest. 1987;80:33\u201340.","journal-title":"J Clin Invest."},{"key":"1370_CR10","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1532\/IJH97.04168","volume":"81","author":"R McMillan","year":"2005","unstructured":"McMillan R, Nugent D. The effect of antiplatelet autoantibodies on megakaryocytopoiesis. Int J Hematol. 2005;81:94\u20139.","journal-title":"Int J Hematol"},{"key":"1370_CR11","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1749-6632.1965.tb18984.x","volume":"124","author":"NR Shulman","year":"1965","unstructured":"Shulman NR, Marder VJ, Weinrach RS. Similarities between known antiplatelet antibodies and the factor responsible for thrombocytopenia in idiopathic purpura. Physiologic, serologic and isotopic studies. Ann NY Acad Sci. 1965;124:499\u2013542.","journal-title":"Ann NY Acad Sci"},{"key":"1370_CR12","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1056\/NEJMe0707126","volume":"357","author":"RS Schwartz","year":"2007","unstructured":"Schwartz RS. Immune thrombocytopenic purpura-from agony to agonist. N Engl J Med. 2007;357:2299\u2013301.","journal-title":"N Engl J Med"},{"key":"1370_CR13","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1532\/IJH97.04193","volume":"81","author":"Y Tomiyama","year":"2005","unstructured":"Tomiyama Y, Kosugi S. Autoantigenic epitopes on platelet glycoproteins. Int J Hematol. 2005;81:100\u20135.","journal-title":"Int J Hematol"},{"key":"1370_CR14","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1046\/j.1538-7836.2003.00091.x","volume":"1","author":"R McMillan","year":"2003","unstructured":"McMillan R, Wang L, Tani P. Prospective evaluation of the immunobead assay for the diagnosis of adult chronic immune thrombocytopenic purpura (ITP). J Thromb Haemost. 2003;1:485\u201391.","journal-title":"J Thromb Haemost"},{"key":"1370_CR15","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1182\/blood.V98.6.1819","volume":"98","author":"S Kosugi","year":"2001","unstructured":"Kosugi S, Tomiyama Y, Honda S, Kato H, Kiyoi T, Kashiwagi H, et al. Platelet-associated anti-GPIIb-IIIa autoantibodies in chronic immune thrombocytopenic purpura recognizing epitopes close to the ligand-binding site of glycoprotein (GP) IIb. Blood. 2001;98:1819\u201327.","journal-title":"Blood"},{"key":"1370_CR16","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2012-02-409995","volume":"120","author":"K Kiyomizu","year":"2012","unstructured":"Kiyomizu K, Kashiwagi H, Nakazawa T, Tadokoro S, Honda S, Kanakura Y, et al. Recognition of highly restricted regions in the \u03b2-propeller domain of \u03b1IIb by platelet-associated anti-\u03b1IIb\u03b23 autoantibodies in primary immune thrombocytopenia. Blood. 2012;120:1499\u2013509.","journal-title":"Blood"},{"key":"1370_CR17","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1182\/blood.V86.10.3789.bloodjournal86103789","volume":"86","author":"R He","year":"1995","unstructured":"He R, Reid DM, Jones CE, Shulman NR. Extracellular epitopes of platelet glycoprotein Ib alpha reactive with serum antibodies from patients with chronic idiopathic thrombocytopenic purpura. Blood. 1995;86:3789\u201396.","journal-title":"Blood"},{"key":"1370_CR18","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1182\/blood.V100.4.1388.h81602001388_1388_1398","volume":"100","author":"JH Roark","year":"2002","unstructured":"Roark JH, Bussel JB, Cines DB, Siegel DL. Genetic analysis of autoantibodies in idiopathic thrombocytopenic purpura reveals evidence of clonal expansion and somatic mutation. Blood. 2002;100:1388\u201398.","journal-title":"Blood"},{"key":"1370_CR19","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1055\/s-0037-1615754","volume":"85","author":"R McMillan","year":"2001","unstructured":"McMillan R, Lopez-Dee J, Bowditch R. Clonal restriction of platelet-associated anti-GPIIb\/IIIa autoantibodies in patients with chronic ITP. Thromb Haemost. 2001;85:821\u20133.","journal-title":"Thromb Haemost"},{"key":"1370_CR20","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0092-8674(01)00477-9","volume":"106","author":"M Nardi","year":"2001","unstructured":"Nardi M, Tomlinson S, Greco MA, Karpatkin S. Complement-independent, peroxide-induced antibody lysis of platelets in HIV-1-related immune thrombocytopenia. Cell. 2001;106:551\u201361.","journal-title":"Cell"},{"key":"1370_CR21","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1182\/blood-2008-09-181073","volume":"113","author":"W Zhang","year":"2009","unstructured":"Zhang W, Nardi MA, Borkowsky W, Li Z, Karpatkin S. Role of molecular mimicry of hepatitis C virus protein with platelet GPIIIa in hepatitis C-related immunologic thrombocytopenia. Blood. 2009;113:4086\u201393.","journal-title":"Blood"},{"key":"1370_CR22","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1046\/j.1365-2141.2003.04735.x","volume":"124","author":"T Takahashi","year":"2004","unstructured":"Takahashi T, Yujiri T, Shinohara K, Inoue Y, Sato Y, Fujii Y, et al. Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H. pylori-associated chronic idiopathic thrombocytopenic purpura. Br J Haematol. 2004;124:91\u20136.","journal-title":"Br J Haematol"},{"key":"1370_CR23","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1172\/JCI4238","volume":"102","author":"M Kuwana","year":"1998","unstructured":"Kuwana M, Kaburaki J, Ikeda Y. Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura. Role in production of anti-platelet autoantibody. J Clin Invest. 1998;102:1393\u2013402.","journal-title":"J Clin Invest"},{"key":"1370_CR24","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood-2003-07-2268","volume":"103","author":"FP Panitsas","year":"2004","unstructured":"Panitsas FP, Theodoropoulou M, Kouraklis A, Karakantza M, Theodorou GL, Zoumbos NC, et al. Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. Blood. 2004;103:2645\u20137.","journal-title":"Blood"},{"key":"1370_CR25","doi-asserted-by":"crossref","first-page":"e26522","DOI":"10.1371\/journal.pone.0026522","volume":"6","author":"Y Hu","year":"2011","unstructured":"Hu Y, Ma DX, Shan NN, Zhu YY, Liu XG, Zhang L, et al. Increased number of Tc17 and correlation with Th17 cells in patients with immune thrombocytopenia. PLoS ONE. 2011;6:e26522.","journal-title":"PLoS ONE"},{"key":"1370_CR26","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1182\/blood-2007-02-068999","volume":"110","author":"R Stasi","year":"2007","unstructured":"Stasi R, Del Poeta G, Stipa E, Evangelista ML, Trawinska MM, Cooper N, et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood. 2007;110:2924\u201330.","journal-title":"Blood"},{"key":"1370_CR27","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/nm921","volume":"9","author":"B Olsson","year":"2003","unstructured":"Olsson B, Andersson PO, Jern\u00e5s M, Jacobsson S, Carlsson B, Carlsson LM, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 2003;9:1123\u20134.","journal-title":"Nat Med"},{"key":"1370_CR28","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/ni1178","volume":"6","author":"S Sakaguchi","year":"2005","unstructured":"Sakaguchi S. Naturally arising Foxp3-expressing CD25\u00a0+\u00a0CD4\u00a0+\u00a0regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005;6:345\u201352.","journal-title":"Nat Immunol"},{"key":"1370_CR29","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.thromres.2006.09.008","volume":"120","author":"M Sakakura","year":"2007","unstructured":"Sakakura M, Wada H, Tawara I, Nobori T, Sugiyama T, Sagawa N, et al. Reduced Cd4\u00a0+\u00a0Cd25\u00a0+\u00a0T cells in patients with idiopathic thrombocytopenic purpura. Thromb Res. 2007;120:187\u201393.","journal-title":"Thromb Res"},{"key":"1370_CR30","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1182\/blood-2008-01-135335","volume":"112","author":"J Yu","year":"2008","unstructured":"Yu J, Heck S, Patel V, Zhu XJ, Hou Y, Jun P, et al. Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood. 2008;112:1325\u20138.","journal-title":"Blood"},{"key":"1370_CR31","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.exphem.2012.01.001","volume":"40","author":"T Nishimoto","year":"2012","unstructured":"Nishimoto T, Satoh T, Takeuchi T, Ikeda Y, Kuwana M. Critical role of CD4(+)CD25(+) regulatory T cells in preventing murine autoantibody-mediated thrombocytopenia. Exp Hematol. 2012;40:279\u201389.","journal-title":"Exp Hematol"},{"key":"1370_CR32","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/jth.12079","volume":"11","author":"T Nishimoto","year":"2013","unstructured":"Nishimoto T, Satoh T, Simpson EK, Ni H, Kuwana M. Predominant autoantibody response to GPIb\/IX in a regulatory T-cell-deficient mouse model for immune thrombocytopenia. J Thromb Haemost. 2013;11:369\u201372.","journal-title":"J Thromb Haemost"},{"key":"1370_CR33","doi-asserted-by":"crossref","unstructured":"Stasi R, Cooper N, Del Poeta G, Stipa E, Laura Evangelista M, Abruzzese E, et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood. 2008;112:1147\u201350.","DOI":"10.1182\/blood-2007-12-129262"},{"key":"1370_CR34","first-page":"262","volume":"9","author":"R Stasi","year":"2011","unstructured":"Stasi R. Pathophysiology and therapeutic options in primary immune thrombocytopenia. Blood Tranfus. 2011;9:262\u201373.","journal-title":"Blood Tranfus"},{"key":"1370_CR35","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1182\/blood-2008-07-166439","volume":"113","author":"A Podolanczuk","year":"2009","unstructured":"Podolanczuk A, Lazarus AH, Crow AR, Grossbard E, Bussel JB. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood. 2009;113:3154\u201360.","journal-title":"Blood"},{"key":"1370_CR36","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1126\/science.291.5503.484","volume":"291","author":"A Samuelsson","year":"2001","unstructured":"Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 2001;291:484\u20136.","journal-title":"Science"},{"key":"1370_CR37","first-page":"2939","volume":"118","author":"A Asahi","year":"2008","unstructured":"Asahi A, Nishimoto T, Okazaki Y, Suzuki H, Masaoka T, Kawakami Y, et al. Helicobacter pylori eradication shifts monocyte Fc gamma receptor balance toward inhibitory Fc gamma RIIB in immune thrombocytopenic purpura patients. J Clin Invest. 2008;118:2939\u201349.","journal-title":"J Clin Invest"},{"key":"1370_CR38","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1182\/blood-2010-07-295477","volume":"117","author":"XG Liu","year":"2011","unstructured":"Liu XG, Ma SH, Sun JZ, Ren J, Shi Y, Sun L, et al. High-dose dexamethasone shifts the balance of stimulatory and inhibitory Fc gamma receptors on monocytes in patients with primary immune thrombocytopenia. Blood. 2011;117:2061\u20139.","journal-title":"Blood"},{"key":"1370_CR39","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1365-2141.1986.tb05552.x","volume":"63","author":"T Tsubakio","year":"1986","unstructured":"Tsubakio T, Tani P, Curd JG, McMillan R. Complement activation in vitro by antiplatelet antibodies in chronic immune thrombocytopenic purpura. Br J Haematol. 1986;63:293\u2013300.","journal-title":"Br J Haematol"},{"key":"1370_CR40","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1365-2141.2009.07995.x","volume":"148","author":"EI Peerschke","year":"2010","unstructured":"Peerschke EI, Andemariam B, Yin W, Bussel JB. Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpura. Br J Haematol. 2010;148:638\u201345.","journal-title":"Br J Haematol"},{"key":"1370_CR41","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1600-0609.2011.01718.x","volume":"88","author":"A Najaoui","year":"2012","unstructured":"Najaoui A, Bakchoul T, Stoy J, Bein G, Rummel MJ, Santoso S, et al. Autoantibody-mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP). Eur J Haematol. 2012;88:167\u201374.","journal-title":"Eur J Haematol"},{"key":"1370_CR42","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1182\/blood-2009-09-244772","volume":"115","author":"L Chow","year":"2010","unstructured":"Chow L, Aslam R, Speck ER, Kim M, Cridland N, Webster ML, et al. A murine model of severe immune thrombocytopenia is induced by antibody- and CD8\u00a0+\u00a0T cell-mediated responses that are differentially sensitive to therapy. Blood. 2010;115:1247\u201353.","journal-title":"Blood"},{"key":"1370_CR43","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2003-01-0275","volume":"103","author":"EJ Houwerzijl","year":"2004","unstructured":"Houwerzijl EJ, Blom NR, van der Want JJ, Esselink MT, Koornstra JJ, Smit JW, et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood. 2004;103:500\u20136.","journal-title":"Blood"},{"key":"1370_CR44","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1182\/blood.V96.13.4169","volume":"96","author":"A Lepage","year":"2000","unstructured":"Lepage A, Leboeuf M, Cazenave JP, de la Salle C, Lanza F, Uzan G. The alpha(IIb)beta(3) integrin and GPIb-V-IX complex identify distinct stages in the maturation of CD34(+) cord blood cells to megakaryocytes. Blood. 2000;96:4169\u201377.","journal-title":"Blood"},{"key":"1370_CR45","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood-2002-05-1475","volume":"102","author":"M Chang","year":"2003","unstructured":"Chang M, Nakagawa PA, Williams SA, Schwartz MR, Imfeld KL, Buzby JS, et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood. 2003;102:887\u201395.","journal-title":"Blood"},{"key":"1370_CR46","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1182\/blood-2003-08-2672","volume":"103","author":"R McMillan","year":"2004","unstructured":"McMillan R, Wang L, Tomer A, Nichol J, Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood. 2004;103:1364\u20139.","journal-title":"Blood"},{"key":"1370_CR47","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3109\/09537104.2012.669508","volume":"24","author":"J Perdomo","year":"2013","unstructured":"Perdomo J, Yan F, Chong BH. A megakaryocyte with no platelets: anti-platelet antibodies, apoptosis, and platelet production. Platelets. 2013;24:98\u2013106.","journal-title":"Platelets"},{"key":"1370_CR48","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1182\/blood-2010-02-267435","volume":"116","author":"L Yang","year":"2010","unstructured":"Yang L, Wang L, Zhao CH, Zhu XJ, Hou Y, Jun P, et al. Contributions of TRAIL-mediated megakaryocyte apoptosis to impaired megakaryocyte and platelet production in immune thrombocytopenia. Blood. 2010;116:4307\u201316.","journal-title":"Blood"},{"key":"1370_CR49","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1365-2141.2007.06737.x","volume":"139","author":"S Li","year":"2007","unstructured":"Li S, Wang L, Zhao C, Li L, Peng J, Hou M. CD8\u00a0+\u00a0T cells suppress autologous megakaryocyte apoptosis in idiopathic thrombocytopenic purpura. Br J Haematol. 2007;139:605\u201311.","journal-title":"Br J Haematol"},{"key":"1370_CR50","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1182\/blood.V65.3.584.584","volume":"65","author":"D Stoll","year":"1985","unstructured":"Stoll D, Cines DB, Aster RH, Murphy S. Platelet kinetics in patients with idiopathic thrombocytopenic purpura and moderate thrombocytopenia. Blood. 1985;65:584\u20138.","journal-title":"Blood"},{"key":"1370_CR51","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1309\/RAW2-0LQW-8YTX-941V","volume":"115","author":"Y Kurata","year":"2001","unstructured":"Kurata Y, Hayashi S, Kiyoi T, Kosugi S, Kashiwagi H, Honda S, et al. Diagnostic value of tests for reticulated platelets, plasma glycocalicin, and thrombopoietin levels for discriminating between hyperdestructive and hypoplastic thrombocytopenia. Am J Clin Pathol. 2001;115:656\u201364.","journal-title":"Am J Clin Pathol"},{"key":"1370_CR52","first-page":"1039","volume":"57","author":"S Hayashi","year":"2009","unstructured":"Hayashi S, Nishiyama M, Suehisa E, Kashiwagi H, Kurata Y, Tomiyama Y. Comparison between two methods for the measurement reticulated platelet and their clinical significance\u2013flow cytometry (FCM) method and IPF method Using automated hematology analyzer (XE-2000). Rinsho Byori. 2009;57:1039\u201344.","journal-title":"Rinsho Byori."},{"key":"1370_CR53","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1056\/NEJM199809103391107","volume":"339","author":"K Kaushansky","year":"1998","unstructured":"Kaushansky K. Thrombopoietin. N Engl J Med. 1998;339:746\u201354.","journal-title":"N Engl J Med"},{"key":"1370_CR54","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.hoc.2009.09.001","volume":"23","author":"DJ Kuter","year":"2009","unstructured":"Kuter DJ, Gernsheimer TB. Thrombopoietin and platelet production in chronic immune thrombocytopenia. Hematol Oncol Clin North Am. 2009;23:1193\u2013211.","journal-title":"Hematol Oncol Clin North Am"},{"key":"1370_CR55","doi-asserted-by":"crossref","unstructured":"Porcelijn L, Folman CC, Bossers B, Huiskes E, Overbeeke MA, van der Schoot CE, et al. The diagnostic value of thrombopoietin level measurements in thrombocytopenia. Thromb Haemost. 1998;79:1101\u20135.","DOI":"10.1055\/s-0037-1615023"},{"key":"1370_CR56","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1182\/blood-2008-07-167155","volume":"113","author":"R Stasi","year":"2009","unstructured":"Stasi R, Sarpatwari A, Segal JB, Osborn J, Evangelista ML, Cooper N, et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood. 2009;113:1231\u201340.","journal-title":"Blood"},{"key":"1370_CR57","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1182\/blood-2004-03-1168","volume":"104","author":"K Kojouri","year":"2004","unstructured":"Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood. 2004;104:2623\u201334.","journal-title":"Blood"},{"key":"1370_CR58","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/blood.V98.12.3241","volume":"98","author":"J Li","year":"2001","unstructured":"Li J, Yang C, Xia Y, Bertino A, Glaspy J, Roberts M, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001;98:3241\u20138.","journal-title":"Blood"},{"key":"1370_CR59","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1182\/blood-2006-10-019315","volume":"109","author":"DJ Kuter","year":"2007","unstructured":"Kuter DJ. New thrombopoietic growth factors. Blood. 2007;109:4607\u201316.","journal-title":"Blood"},{"key":"1370_CR60","doi-asserted-by":"crossref","unstructured":"Tomiyama Y. Thrombopoietin receptor agonists. Current & emerging treatments for Immune Thrombocytopenia. (Salama A edit) Future Medicine, UK, 2013, pp 88\u2013106.","DOI":"10.2217\/ebo.12.186"},{"key":"1370_CR61","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.exphem.2004.09.006","volume":"33","author":"CL Erickson-Miller","year":"2005","unstructured":"Erickson-Miller CL, DeLorme E, Tian SS, Hopson CB, Stark K, Giampa L, et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol. 2005;33:85\u201393.","journal-title":"Exp Hematol"},{"key":"1370_CR62","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0140-6736(10)60959-2","volume":"377","author":"G Cheng","year":"2011","unstructured":"Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011;377:393\u2013402.","journal-title":"Lancet"},{"key":"1370_CR63","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2012-04-425512","volume":"121","author":"MN Saleh","year":"2013","unstructured":"Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia (ITP): results of the long-term, open-label EXTEND study. Blood. 2013;121:537\u201345.","journal-title":"Blood"},{"key":"1370_CR64","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3999\/jscpt.42.11","volume":"42","author":"Y Shida","year":"2011","unstructured":"Shida Y, Takahashi N, Nohda S, Hirama T. Pharmacokinetics and pharmacodynamics of eltrombopag in healthy Japanese males. Jpn J Clin Pharmacol Ther. 2011;42:11\u201320.","journal-title":"Jpn J Clin Pharmacol Ther"},{"key":"1370_CR65","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1177\/0091270010375427","volume":"51","author":"E Gibiansky","year":"2011","unstructured":"Gibiansky E, Zhang J, Williams D, Wang Z, Ouellet D. Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura. J Clin Pharmacol. 2011;51:842\u201356.","journal-title":"J Clin Pharmacol"},{"key":"1370_CR66","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1538-7836.2012.04695.x","volume":"10","author":"Y Tomiyama","year":"2012","unstructured":"Tomiyama Y, Miyakawa Y, Okamoto S, Katsutani S, Kimura A, Okoshi Y, et al. A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia. J Thromb Haemost. 2012;10:799\u2013806.","journal-title":"J Thromb Haemost"},{"key":"1370_CR67","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0140-6736(08)60203-2","volume":"371","author":"DJ Kuter","year":"2008","unstructured":"Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008;371:395\u2013403.","journal-title":"Lancet"},{"key":"1370_CR68","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1002625","volume":"363","author":"DJ Kuter","year":"2010","unstructured":"Kuter DJ, Rummel M, Boccia R, Macik BG, Pabinger I, Selleslag D, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med. 2010;363:1889\u201399.","journal-title":"N Engl J Med"},{"key":"1370_CR69","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/ajh.20992","volume":"83","author":"R McMillan","year":"2008","unstructured":"McMillan R, Bussel JB, George JN, Lalla D, Nichol JL. Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol. 2008;83:150\u20134.","journal-title":"Am J Hematol"},{"key":"1370_CR70","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s12185-012-1065-2","volume":"95","author":"Y Shirasugi","year":"2012","unstructured":"Shirasugi Y, Ando K, Miyazaki K, Tomiyama Y, Iwato K, Okamoto S, et al. An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5\u00a0years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP). Int J Hematol. 2012;95:652\u20139.","journal-title":"Int J Hematol"},{"key":"1370_CR71","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","volume":"83","author":"ME Reff","year":"1994","unstructured":"Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435\u201345.","journal-title":"Blood"},{"key":"1370_CR72","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ctrv.2005.05.007","volume":"31","author":"E Kimby","year":"2005","unstructured":"Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev. 2005;31:456\u201373.","journal-title":"Cancer Treat Rev"},{"key":"1370_CR73","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2165\/00003495-200666060-00005","volume":"66","author":"RS Cvetkovic","year":"2006","unstructured":"Cvetkovic RS, Perry CM. Rituximab: a review of its use in non-Hodgkin\u2019s lymphoma and chronic lymphocytic leukaemia. Drugs. 2006;66:791\u2013820.","journal-title":"Drugs"},{"key":"1370_CR74","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2141.2008.07054.x","volume":"141","author":"B Garvey","year":"2008","unstructured":"Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol. 2008;141:149\u201369.","journal-title":"Br J Haematol"},{"key":"1370_CR75","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7326\/0003-4819-146-1-200701020-00006","volume":"146","author":"DM Arnold","year":"2007","unstructured":"Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med. 2007;146:25\u201333.","journal-title":"Ann Intern Med"},{"key":"1370_CR76","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-11-393975","volume":"119","author":"VL Patel","year":"2012","unstructured":"Patel VL, Mah\u00e9vas M, Lee SY, Stasi R, Cunningham-Rundles S, Godeau B, et al. Outcomes 5\u00a0years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. 2012;119:5989\u201395.","journal-title":"Blood"},{"key":"1370_CR77","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.3324\/haematol.11709","volume":"92","author":"D Provan","year":"2007","unstructured":"Provan D, Butler T, Evangelista ML, Amadori S, Newland AC, Stasi R. Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. Haematologica. 2007;92:1695\u20138.","journal-title":"Haematologica"},{"key":"1370_CR78","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1600-0609.2010.01486.x","volume":"85","author":"F Zaja","year":"2010","unstructured":"Zaja F, Vianelli N, Volpetti S, Battista ML, Defina M, Palmieri S, et al. Low-dose rituximab in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2010;85:329\u201334.","journal-title":"Eur J Haematol"},{"key":"1370_CR79","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/ajh.21512","volume":"84","author":"A Hasan","year":"2009","unstructured":"Hasan A, Michel M, Patel V, Stasi R, Cunningham-Rundles S, Leonard JP, et al. Repeated courses of rituximab in chronic ITP: three different regimens. Am J Hematol. 2009;84:661\u20135.","journal-title":"Am J Hematol"},{"key":"1370_CR80","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","volume":"117","author":"C Neunert","year":"2011","unstructured":"Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA, American Society of Hematology. The American Society of Hematology 2011 evidence-based practical guideline for immune thrombocytopenia. Blood. 2011;117:4190\u2013207.","journal-title":"Blood"},{"key":"1370_CR81","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1182\/blood-2002-02-0392","volume":"99","author":"R Stasi","year":"2002","unstructured":"Stasi R, Stipa E, Forte V, Meo P, Amadori S. Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura. Blood. 2002;99:3872\u20133.","journal-title":"Blood"},{"key":"1370_CR82","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/ncprheum0424","volume":"3","author":"RP Taylor","year":"2007","unstructured":"Taylor RP, Lindorfer MA. Drug insight: the mechanism of action of rituximab in autoimmune disease\u2013the immune complex decoy hypothesis. Nat Clin Pract Rheumatol. 2007;3:86\u201395.","journal-title":"Nat Clin Pract Rheumatol"},{"key":"1370_CR83","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1182\/blood-2011-03-344051","volume":"118","author":"S Audia","year":"2011","unstructured":"Audia S, Samson M, Guy J, Janikashvili N, Fraszczak J, Trad M, et al. Immunologic effects of rituximab on the human spleen in immune thrombocytopenia. Blood. 2011;118:4394\u2013400.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-013-1370-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-013-1370-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-013-1370-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T01:59:39Z","timestamp":1595815179000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-013-1370-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,24]]},"references-count":83,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["1370"],"URL":"https:\/\/doi.org\/10.1007\/s12185-013-1370-4","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,24]]}}}